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Huntington disease is a common example used for initi-
ating discussion about presymptomatic genetic testing
when no therapeutic intervention is available. Recent
work in mice provides a glimmer of hope that this might
not always be true. Budworth et al. knew that the enzyme
OGG1 is involved in DNA repair and, as a by-product,
contributes to Htt-repeat instability. Because loss of
OGG1 activity prevents somatic expansion of Htt repeats,
Budworth et al. used this as a tool to explore in mice
the role of somatic expansion in the age of onset of
Huntington disease. Whether as a result of genetic loss or
pharmacological inhibition of OGG1, preventing somatic
expansion delayed the motor symptoms in mice with an
Htt mutation. Loss of OGG1 activity itself didn’t appear
to have negative effects in the mice, so this work provides
a potential therapeutic target that might eventually be
used to delay the onset of Huntington disease in people
who have a positive presymptomatic test.
Budworth et al. (2015). PLoS Genet. 11, e1005267.
Population Studies of Copy-Number Variation
Large-scale population studies based on genome-wide
single-nucleotide variation have illuminated the relation-
ships between human populations and given us a greater
understanding of human history. Fewer studies have
explored population differences at the level of copy-
number variation (CNV). Sudmant et al. decided to give
it a shot and used whole-genome sequencing to assess
CNVs in 125 human populations. Through principal-
component analysis, they used CNVs to separate the
major human populations, although this worked better
when they used deletions rather than duplications.
Despite this difference, duplications were more likely
to show population stratification than were deletions.
This is particularly intriguing given the fact that dupli-
cations were also under weaker selective constraint
and more likely to include genes than were deletions,
intimating that duplications could plausibly underlie dif-
ferences in risk for certain traits between populations.
Comparisons between their human samples and the
chimpanzee and orangutan genomes uncovered deletions
that occurred in the human lineage specifically, whereas
comparisons with the Denisova genome revealed a dupli-
cation that is shared between the Denisova and Papuan
samples and represents the largest introgressed archaic1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americhominin locus that has been described to date in modern
humans.
Sudmant et al. (2015). Science. Published online August 6,
2015. http://dx.doi.org/10.1126/science.aab3761.
Not So Innocuous
Infection with adeno-associated virus type 2 (AAV2) is very
common in humans. Because it elicits a mild immune
response and because it yields no apparent disease, AAV2
has been engineered as a delivery vector for various gene-
therapy approaches. Now, Nault et al. have found evidence
that in rare natural infections, AAV2might insert itself into
cancer driver genes and contribute to hepatocellular carci-
noma (HCC). The authors sought previously unreported
risk factors for HCC and found clonal AAV2 insertions in
11 of 193 HCC samples, largely in non-cirrhotic livers
without known risk factors for HCC. Four of the insertions
occurred near CCNA2—two near TNFSF10 and two near
CCNE1—and all increased the expression of the neigh-
boring driver gene. AAV2 might not be as innocuous as
once believed, but given the fact that nearly half of the
population has evidence of a prior infection with AAV2,
we don’t fully understand the oncogenic risk associated
with this virus.
Nault et al. (2015). Nat. Genet. Published online August 24,
2015. http://dx.doi.org/10.1038/ng.3389.
Red Herring for Obesity
In multiple genome-wide association studies, one of the
strongest genetic associations for obesity has been a region
within FTO, a finding that has generated interest in the
function of this gene. The association signal is found
within a linkage-disequilibrium block that spans nearly
90 SNPs and 50 kb, a feature that makes it difficult to
uncover the critical genetic variation and determine how
it contributes to obesity. Recent work by Claussnitzer
et al. suggests that the location of this association within
FTO is a red herring and that the functional effect of this
variation is via long-range regulation of two independent
genes: IRX3 and IRX5. The risk haplotype at FTO can be
narrowed to a single SNP allele that disrupts ARID5B-
mediated repression of IRX3 and IRX5 expression during
adipocyte differentiation. The resulting increase in the
amount of IRX3 and IRX5, in turn, puts the cells on a
developmental trajectory toward energy-storing white
adipocytes and away from thermogenic beige adipocytes.ta, GA 30322, USA
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CRISPR-mediated editing of this single nucleotide shifts
cells between these two outcomes, re-focusing attention
in this region from FTO to IRX3 and IRX5 for their role
in obesity susceptibility.
Claussnitzer et al. (2015). N. Engl. J. Med. 373, 895–907.
Targeting Cancer
There has been much talk recently of revolutionizing
cancer classification so that it is based on underlying mu-
tations rather than the tissue affected. In theory, these
molecular groupings could facilitate treatment selection
via selective targeting of the mutations. One such muta-
tion is BRAF V600, which is associated with constitutive
activation of the MAP kinase pathway and is selectively506 The American Journal of Human Genetics 97, 505–506, Octoberinhibited by vemurafenib. Although this drug was origi-
nally designed to treat melanomas, many of which
contain BRAF V600, the presence of this variant in a vari-
ety of other cancers led Hyman et al. to a trial of vemur-
afenib in a range of nonmelanoma cancers. Although
many BRAF-V600-positive tumors responded to treat-
ment, the response differed by cancer type. Non-small-
cell lung cancers, for example, tended to respond to the
therapy, whereas colorectal tumors did not. Although it
is still a promising treatment, this early trial suggests
that it is naive to think that a single mutation will
completely define the proper classification and treatment
of a wide swath of cancers.
Hyman et al. (2015). N. Engl. J. Med. 373, 726–735.This Month in Our Sister JournalsSelecting the Best Representative
Genotype imputation can give you more bang for
your sequence buck. Starting with a densely genotyped
reference panel, one can infer unobserved genotypes
in a larger sample on which less genotyping is actually
performed. Just which reference panel to use becomes
an issue that can influence the accuracy of the impu-
tation. Some methods for reference-panel selection
attempt to maximize the diversity of the referencepanel. Instead, Kang et al. decided to base their selec-
tion procedure on the panel’s representativeness of
the larger sample through the use of an average-dis-
tance-to-closest-leaf (ADCL) approach. In simulated and
real datasets, the ADCL approach improved their impu-
tation accuracy, particularly for low-frequency genetic
variation.
Kang et al. (2015). Genetics. Published online August 24,
2015. http://dx.doi.org/10.1534/genetics/115/176909.1, 2015
